https://www.thebodypro.com/article/two-drug-hiv-treatment-long-term-inflammation
HIV Treatment StrategiesConference Coverage

As Two-Drug HIV Treatment Rises, Long-Term Inflammation Becomes a Potential Concern

hand showing 2
kieferpix via iStock
    • “Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV,” AIDSinfo. December 18, 2019. aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0

    • “European AIDS Clinical Society Guidelines version 10.0 (Nov 2019),” European AIDS Clinical Society. eacs.sanfordguide.com/

    • “Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation,” Sergio Serrano-Villar et al. 23rd International AIDS Conference, July 2020.

    • “Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study,” Jean van Wyk et al. 23rd International AIDS Conference, July 2020.

    • “Is DTG+3TC effective and safe in clinical practice? Evidence from real world data,” Yogesh Punekar et al. 23rd International AIDS Conference, July 2020.

    • “Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis,” Katharina Nickel et al. 23rd International AIDS Conference, July 2020.

    • “Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR),” Esteban Martinez et al. 23rd International AIDS Conference, July 2020.

    • “Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1 infection,” Chloe Orkin et al. 23rd International AIDS Conference, July 2020.

    • “Islatravir safety analysis through week 48 from a phase 2 trial in treatment naïve adults with HIV-1 infection,” Edwin DeJesus et al. 23rd International AIDS Conference, July 2020.

    Myles Helfand

    Myles Helfand

    @MylesatTheBody

    Myles Helfand is the executive editor and general manager of TheBody/TheBodyPro.